Abstract
We studied COVID-19 case mortality in Florida among four successive cohorts of persons at least 50 years of age, each of whom we followed for 28 to 48 days from date of diagnosis. The cohorts were separated by date of diagnosis into four nonoverlapping intervals: March 29 - April 18; April 29 - May 19; May 21 - June 10; and June 14 - July 4, 2020. Case mortality rates declined consistently and significantly over the course of the four intervals: 57% among those aged 50-59 years; 62% among those aged 60-69 years; 52% among those aged 70-79 years; and 34% among those aged 80 or more years. These findings were consistent with progressive improvements in the medical care of COVID-19 patients. We further studied case mortality by hospitalization status. The case mortality rate among hospitalized patients aged 60-69 years fell significantly from the first to the third interval. During the fourth interval, an apparent rise in mortality among hospitalized patients in the same age group was mirrored by a significant decline in mortality among those not hospitalized. These findings were consistent with the out-of-hospital treatment of some patients who would have previously been hospitalized.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding sources.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study relies exclusively on publicly available, aggregate health data that contain no individual identifiers.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The underlying data links are provided in the article. The author will make all intermediate programs and output available.
